Measuring Cell-Free DNA in Follicular Lymphoma
This study is looking at how levels of cell-free DNA (cfDNA) in your blood change before, during, and after your first treatment for follicular lymphoma. Researchers want to see if these cfDNA levels can help predict how well you respond to standard treatment. They are also investigating how different genetic changes in follicular lymphoma affect treatment response. You may be able to join if you are at least 18 years old and have follicular lymphoma that has been confirmed by a biopsy. The study aims to determine if cfDNA testing can accurately identify the presence of disease compared to standard imaging like PET/CT scans. The current recruitment status is unclear.
- Study design
- This study is an interventional study with a planned enrollment of 77 participants. It is not a therapeutic study, meaning it does not test a new treatment.
- What's involved
- You will provide blood samples before treatment, after 2 cycles of therapy, at the end of 6-8 cycles, and then every 6 months for 2 years. You will also provide a saliva or fingernail clipping once, and undergo PET/CT, CT, or MRI scans at specific times.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 2 years from the start of therapy to see if the cfDNA assay can correctly identify the presence of disease.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
At a glance
Conditions
Where it's being run
7 sites across 2 statesStudy leadership
- Paola Ghione, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- whether the assay can correctly identify presence of disease in patients with measurable disease2 years
Response will be evaluated using the updated response criteria entitled, "The Lugano Classification" system. The investigator will use of the 5-point scale for visually assessing response on the pre- and end-of-treatment FDGPET/CT scans. This scale is commonly referred to as the Deauville criteria; it was developed by international experts in the field at the First International Workshop on interim-PET in Lymphoma in Deauville in 2009 and is routinely applied to patients undergoing lymphoma directed therapy. The 5-point scale is described in the table below. 1 No residual uptake 2 Uptake ≤ mediastinum 3 Uptake \> mediastinum but ≤ liver 4 Uptake moderately \> liver 5 Markedly increased uptake at any site or progression